Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02067793 · ClinicalTrials.gov registry record · Phase 2
Study of Intravenous NRX-1074 in Patients With Major Depressive Disorder
A Phase 2 study, sponsored by Naurex, Inc, an affiliate of Allergan.
- Completed
- Registry status
- Phase 2
- Development phase
- 151
- Enrollment target
NCT02067793 is a Phase 2 study that has completed, run by Naurex, Inc, an affiliate of Allergan. The registered enrollment target is 151 participants.
The verdict
NCT02067793, a Phase 2 study, has completed, sponsored by Naurex, Inc, an affiliate of Allergan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 151 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of NRX-1074 following a single intravenous dose in subjects with major depressive disorder.
Interventions
- DRUG Placebo
- DRUG NRX-1074 1 mg
- DRUG NRX-1074 5 mg
- DRUG NRX-1074 10 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 151 participants |
| Start Date | 2014-03 |
| Est. Completion | 2015-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02067793
The ClinicalTrials.gov registry entry for NCT02067793 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 151 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Naurex, Inc, an affiliate of Allergan, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02067793 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02067793 about?
NCT02067793 is a clinical study titled "Study of Intravenous NRX-1074 in Patients With Major Depressive Disorder". The purpose of this study is to evaluate the efficacy and safety of NRX-1074 following a single intravenous dose in subjects with major depressive disorder.
What is the current status of trial NCT02067793?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 151 participants. The study started on 2014-03. Estimated completion is 2015-02.
What interventions are being tested in trial NCT02067793?
The interventions under investigation include: Placebo (DRUG), NRX-1074 1 mg (DRUG), NRX-1074 5 mg (DRUG), NRX-1074 10 mg (DRUG).
Who is sponsoring clinical trial NCT02067793?
This trial is sponsored by Naurex, Inc, an affiliate of Allergan, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.